Phase 3 Neuromyelitis Optica Spectrum Disorder Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche8 enrolled13 locationsNCT05199688
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.12 enrolled21 locationsNCT05346354
Recruiting
Phase 2Phase 3
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd132 enrolled51 locationsNCT06413654